RCT of Olanzapine for Control of CIV in Children Receiving HSCT Conditioning
Summary
- Eligibility
- for people ages 30 months to 18 years (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Christopher Dvorak
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Christopher Dvorak
My Research Interests are divided into 3 areas of focus: 1. Supportive Care (especially Invasive Fungal Infections) following Hematopoietic Stem Cell Transplantation 2. Transplantation for Severe Combined Immunodeficiency 3. Transplantation for Rare Leukemias (JMML and APL)
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- The Hospital for Sick Children
- ID
- NCT03118986
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated